Statin Therapy Worsens Insulin Sensitivity in Women With Polycystic Ovary Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

被引:80
|
作者
Puurunen, Johanna [1 ,4 ,5 ]
Piltonen, Terhi [1 ,4 ,5 ]
Puukka, Katri [3 ,6 ]
Ruokonen, Aimo [3 ]
Savolainen, Markku J. [2 ,4 ,5 ,7 ]
Bloigu, Risto [8 ]
Morin-Papunen, Laure [1 ]
Tapanainen, Juha S. [1 ,4 ,5 ,9 ]
机构
[1] Univ Oulu, Inst Clin Med, Dept Obstet & Gynecol, FI-90014 Oulu, Finland
[2] Univ Oulu, Inst Clin Med, Dept Internal Med, FI-90014 Oulu, Finland
[3] Univ Oulu, Inst Diagnost, Dept Clin Chem, FI-90014 Oulu, Finland
[4] Oulu Univ Hosp, Clin Res Ctr, FI-90014 Oulu, Finland
[5] Oulu Univ Hosp, Med Res Ctr, FI-90014 Oulu, Finland
[6] Oulu Univ Hosp, NordLab Oulu, FI-90014 Oulu, Finland
[7] Univ Oulu, Bioctr Oulu, FI-90014 Oulu, Finland
[8] Univ Oulu, Med Informat & Stat Res Grp, FI-90014 Oulu, Finland
[9] Univ Helsinki, Dept Obstet & Gynecol, FI-00029 Helsinki, Finland
来源
基金
芬兰科学院;
关键词
GLUCOSE-TOLERANCE; ATORVASTATIN; SIMVASTATIN; PREVALENCE; METFORMIN;
D O I
10.1210/jc.2013-2674
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Statins have been shown to improve hyperandrogenism in women with polycystic ovary syndrome (PCOS). However, their use has also been associated with impairment of glucose metabolism and an increased risk of type 2 diabetes mellitus. Because women with PCOS are prone to disturbances in glucose metabolism, statin therapy could also have negative effects. Objective: Our objective was to explore the effects of atorvastatin therapy on hormonal and metabolic parameters in women with PCOS. Design and Setting: We conducted a randomized, double-blind, placebo-controlled 6-month follow-up study conducted at Oulu University Hospital, Finland. Patients: Women with PCOS (Rotterdam criteria) were treated with atorvastatin (20 mg/d, n = 15) or placebo (n = 13) for 6 months. Interventions: Fasting serum samples were collected at baseline and at 3 and 6 months. Oral and iv glucose tolerance tests were performed at 0 and 6 months. Main Outcome Measures: Androgen secretion and glucose metabolism were measured. Results: Fasting levels and area under the curve of insulin increased significantly and insulin sensitivity (insulinogenic and Matsuda indexes) decreased during 6 months of atorvastatin therapy. Serum levels of dehydroepiandrosterone sulfate decreased in the atorvastatin group, whereas no change was observed in serum testosterone levels. Levels of C-reactive protein, total and low-density lipoprotein-cholesterol, and triglycerides decreased significantly during statin therapy. Conclusions: Atorvastatin therapy improves chronic inflammation and lipid profile, but it impairs insulin sensitivity in women with PCOS. Because women with PCOS have an increased risk of developing type 2 diabetes mellitus, the results suggest that statin therapy should be initiated on the basis of generally accepted criteria and individual risk assessment of cardiovascular disease, and not only because of PCOS.
引用
收藏
页码:4798 / 4807
页数:10
相关论文
共 50 条
  • [1] STATIN THERAPY IMPAIRS INSULIN SENSITIVITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS): A PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY.
    Puurunen, J.
    Piltonen, T.
    Ruokonen, A.
    Savolainen, M. J.
    Morin-Papunen, L.
    Tapanainen, J. S.
    [J]. FERTILITY AND STERILITY, 2012, 98 (03) : S2 - S2
  • [2] Early effects of metformin in women with polycystic ovary syndrome: A prospective randomized, double-blind, placebo-controlled trial
    Eisenhardt, S
    Schwarzmann, N
    Henschel, V
    Germeyer, A
    von Wolff, M
    Hamann, A
    Strowitzki, T
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (03): : 946 - 952
  • [3] Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study
    Kazerooni, Talieh
    Shojaei-Baghini, Azam
    Dehbashi, Sedigheh
    Asadi, Nasrin
    Ghaffarpasand, Fariborz
    Kazerooni, Yasaman
    [J]. FERTILITY AND STERILITY, 2010, 94 (06) : 2208 - 2213
  • [4] The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study
    Sathyapalan, Thozhukat
    Kilpatrick, Eric S.
    Coady, Anne-Marie
    Atkin, Stephen L.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01): : 103 - 108
  • [5] Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial
    Banaszewska, Beata
    Wrotynska-Barczynska, Joanna
    Spaczynski, Robert Z.
    Pawelczyk, Leszek
    Duleba, Antoni J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11): : 4322 - 4328
  • [7] Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial
    Rezvan, N.
    Moini, A.
    Janani, L.
    Mohammad, K.
    Saedisomeolia, A.
    Nourbakhsh, M.
    Gorgani-Firuzjaee, S.
    Mazaherioun, M.
    Hosseinzadeh-Attar, M. J.
    [J]. HORMONE AND METABOLIC RESEARCH, 2017, 49 (02) : 115 - 121
  • [8] Effect of Sibutramine on Weight Reduction in Women With Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lindholm, Asa
    Bixo, Marie
    Bjorn, Inger
    Wolner-Hanssen, Pal
    Eliasson, Mats
    Larsson, Anders
    Johnson, Owe
    Poromaa, Inger Sundstrom
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2008, 63 (11) : 707 - 709
  • [9] Effect of sibutramine on weight reduction in women with polycystic ovary syndrome:: a randomized, double-blind, placebo-controlled trial
    Lindholm, Asa
    Bixo, Marie
    Bjorn, Inger
    Wolner-Hanssen, Pal
    Eliasson, Mats
    Larsson, Anders
    Johnson, Owe
    Poromaa, Inger Sundstrom
    [J]. FERTILITY AND STERILITY, 2008, 89 (05) : 1221 - 1228
  • [10] Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
    Jamilian, Mehri
    Razavi, Maryamalsadat
    Kashan, Zohreh Fakhrie
    Ghandi, Yasser
    Bagherian, Tayebeh
    Asemi, Zatollah
    [J]. CLINICAL ENDOCRINOLOGY, 2015, 82 (06) : 885 - 891